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Abstract 
Objective: In many cases where Huntington’s disease (HD) is suspected, the genetic test 
for HD is negative: these are known as HD phenocopies.  A repeat expansion in the 
C9orf72 gene has recently been identified as a major cause of familial and sporadic 
frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS). Our 
objective was to determine whether this mutation causes HD phenocopies.   
Methods: A cohort of 514 HD phenocopy patients were analysed for the C9orf72 
expansion using repeat-primed PCR.  In cases where the expansion was found, Southern 
hybridisation was performed to determine expansion size.  Clinical case notes were 
reviewed to determine the phenotype of expansion-positive cases.  
Results: 10 subjects (1.95%) had the expansion, making it the commonest identified 
genetic cause of HD-phenocopy presentations.  The size of expansion was not significantly 
different from that associated with other clinical presentations of C9orf72 expanded cases.  
The C9orf72 expansion-positive subjects were characterised by the presence of movement 
disorders including dystonia, chorea, myoclonus, tremor and rigidity. Furthermore the age 
of onset in this cohort was lower than previously reported for subjects with the C9orf72 
expansion, and included one case with paediatric onset. 
Discussion: This study extends the known phenotype of the C9orf72 expansion, both in 
age of onset and movement disorder symptoms.  We propose a revised clinico-genetic 
algorithm for the investigation of HD-phenocopy patients based on these data. 
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Introduction 
Huntington’s disease (HD) is an autosomal dominantly inherited neurodegenerative 
condition typically characterised by a triad of psychiatric, movement and cognitive 
impairment.  In many cases where HD is suspected clinically, patients lack the CAG repeat 
expansion that causes HD1-4.  Such individuals are said to have HD phenocopy syndromes 
or HD-like disorders5.  Wild & Tabrizi3 reviewed genes identified in different HD phenocopy 
cohorts to determine that Spinocerebellar ataxia 17 (TBP) accounts for 1.1%, Huntington’s 
Disease-Like 2 (HDL2) for 0.7%, Friedreich’s ataxia (JPH3) for 0.35% and inherited prion 
disease (PRNP) for 0.24% of HD phenocopies. Testing for these mutations is now routinely 
performed; however the majority of HD phenocopy patients still do not attain a formal 
genetic diagnosis.    
In 2011 an expanded hexanucleotide repeat in the C9orf72 gene was identified in large 
kindreds with FTLD and ALS6, 7.   This expansion is recognised as the commonest genetic 
cause of ALS and FTLD in many but not all populations6-9.  The mutation is intronic, in a  
highly conserved gene6, 10 which has homology with the DENN-like superfamily suggesting 
a role as regulator of membrane traffic10-12, and which may be involved in other neurological 
conditions13.  Several hundred-thousands of repeats have been documented in pathogenic 
expansions14.  Elucidating the pathogenic mechanism of this expansion has generated 
much interest; several non-mutually exclusive possibilities exist6, 15-19.   
In this study we undertook to examine whether the C9orf72 expansion causes HD 
phenocopy clinical presentations, and hence whether testing for it should be considered in 
the routine genetic work-up of this patient group.   
 
  
 Hensman Moss   5 
 
Subjects and methods 
Case ascertainment 
As previously described20, subjects were classified as having HD phenocopy syndromes on 
the basis of a clinical presentation consistent with HD when assessed by an experienced 
neurologist or neurogeneticist, and a negative test for the expanded CAG repeat in the HTT 
gene which causes HD (<36 repeats).    At the Neurogenetics Unit of the National Hospital 
for Neurology and Neurosurgery (NHNN), London, UK, 63.5% of diagnostic HD tests (those 
done on symptomatic patients) are negative for HD.  A cohort of 514 HD phenocopy cases 
who underwent negative diagnostic genetic testing for HD at NHNN were identified.  The 
average age at onset in this cohort was 48.8 years in those with precise onset data (SD 
19.3, N=176).  300 subjects were seen at NHNN, 214 at other hospitals.  Of those seen at 
NHNN, 45.3% were seen by a Movement Disorders Consultant, 15.3% by a Cognitive 
Disorders Consultant, 14.3% by a Neurogenetics Consultant and 25% by other Consultant 
Neurologists.    
 
Clinical summaries were reviewed for all cases, and all available clinical case notes 
reviewed for cases positive for the C9orf72 expansion mutation.  Demographic data, family 
history, examination findings, first symptoms and age of onset were recorded.  Where 
available, neuropsychometry reports were reviewed, and additional investigations were 
documented including electrophysiological assessments, MRI, CSF and tissue biopsies.  
HTT CAG repeat length was recorded.  Fisher’s exact test (Stata software) was used to 
examine the relationship between the presence of particular clinical signs and gene test 
outcome.  
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All C9orf72-positive cases were given a modified Goldman score21, 22, which was used to 
quantify the strength of the autosomal dominant family history.  
 
Standard Protocol Approvals, Registrations, and Patient Consents 
Ethical approval to undertake these analyses was given by the local NHNN/ION ethics 
committee. Informed consent for genetic studies was obtained from all participants. 
 
Repeat primed PCR (rpPCR) 
To test for the presence of an expansion at C9orf72, rpPCR was carried out as previously 
described7.  Fragment length analysis was undertaken on an ABI 3730xl automated 
sequencer.  Analysis of repeat primed PCR electropherograms was performed using Peak 
Scanner v1.0 (ABI).  Expansions with a characteristic ‘saw-tooth’ pattern were identified 
and put forward for Southern blotting.  
 
Rs3849942 genotyping 
The surrogate marker rs3849942, reported to be associated with an increased risk of 
mutation6, 14, was genotyped by allelic discrimination using the 5’ nuclease assay in 
conjunction with Minor Groove Binding (MGB) probes. The assay was performed on the 
SDS7500 Fast Real Time PCR system (ABI) and genotyping calls were made using 
software v2.0.6. 
 
Southern Hybridisation 
A recently described Southern hybridisation protocol was used14. This combined the use of 
an oligonucleotide (GGGGCC)5 probe which targets multiple sites within the expansion and 
genomic DNA (gDNA) digested with two frequently cutting restriction endonucleases whose 
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sites closely flanked the repeat region. Hexanucleotide repeat number was estimated by 
interpolation of autoradiographs using a plot of log10 base pair number against migration 
distance which was created in Microsoft Excel. 
 
Results 
Genetic analyses 
Of the 514 HD phenocopy cases screened, 10 probands (1.95%, 95% CI 1-4) were positive 
for the C9orf72 expansion, making this mutation the commonest identified cause of HD 
phenocopy syndromes in a UK cohort20.   
Genotyping of the C9orf72-positive cases was consistent with all previous reports in that 
these individuals were either heterozygous or homozygous for the rs3849942 A allele6 
(Table 1).  No C9orf72-positive cases had intermediate sized HD CAG repeats in the 
Huntingtin gene, and there was no correlation between the larger HD normal allele and age 
of onset.  
 
Table 1.  
 
Southern hybridisation (Table 1 and Figure 1) of 8/10 subjects for whom there was 
sufficient DNA demonstrated that the size of expansion in this HD Phenocopy case series 
was not significantly different from that found in series with other clinical presentations of 
the C9orf72 expansion14.  There was no significant difference in expansion size between 
those with and without chorea/dystonia.   
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Figure 1: ‘Southern Blot of eight HD phenocopy patient DNAs’.   
Of the entire cohort, 19.5% had a family history of similar neurodegenerative disease 
whereas 70% of C9orf72-positive cases had a positive family history (see Goldman scores, 
table 1).  These results suggest that there is a predominance of those with family history, 
but sporadic C9orf72-positive cases may be possible.   
 
Clinical features of C9orf72 expansion gene carriers (table 2)  
The mean age of onset was 42.7 years, range 8-60.  Early psychiatric and behavioural 
problems were common; they were the first recorded symptoms in six of the cohort.  
Depression occurred in four, obsessions in two, apathy in two and psychosis in two cases.   
Movement disorders were a prominent feature in this cohort - three exhibited chorea, four 
dystonia, four myoclonus and three tremor.  Six of the ten subjects had rigidity and five 
bradykinesia.  Chorea was observed periorally in one, was generalised with predominant 
head and arm involvement in one, and in the left arm and leg in another.  Of the four 
subjects with dystonia, three were observed to have torticollis.  In four of the ten subjects 
upper motor neuron signs were noted; lower motor neuron signs were not observed in any.   
Cognitively, executive dysfunction was noted in six subjects, and memory impairment was 
present in six; in subject 6 for whom limited history was available, ‘cognitive impairment’ 
was noted. 
Of eight cases with available MRI reports four had generalised atrophy. 
Case 4 was found to be homozygous for the C9orf72 expansion mutation and has been 
described in detail in Fratta et al23.  
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Comparisons between C9orf72 positive cases and the rest of the HD phenocopy 
cohort 
 
To examine whether there are particular HD phenocopy cases in whom C9orf72 testing 
should be prioritized, we compared the frequencies of symptoms and signs between the 
whole cohort and those with the expansion (table 3).  Fisher’s exact test was performed to 
investigate association between each clinical feature and the outcome of the C9orf72 
genetic test.  The presence of cognitive and psychiatric features, and some movement 
disorder features (dystonia, bradykinesia/rigidity, tremor, myoclonus and upper motor 
neuron features), were significantly associated with a positive C9orf72 test (table 3).  
Though there may be some degree of ascertainment bias as more clinical detail was 
recorded for positive cases, it remains clear that many symptoms characteristic of HD 
phenocopies are associated with a C9orf72 gene expansion.   
 
An illustrative case: 
Case 5, a right-handed Caucasian woman, had a normal birth and development and was 
university educated.  She worked in a professional job and was well until a sudden 
bereavement when she was fifty after which she became depressed.  
At around 55y increasing fatigue was noted and she had her first falls, initially backwards.  
She stopped working, and developed a change in personality with decreased interest in her 
environment and child-like behaviour.  She developed hypophonia and slurred speech.   
By 58y she was having difficulty mobilizing and within 12 months went from independent-
living to being mute, profoundly bradykinetic and requiring a hoist to transfer. She 
developed dystonic posturing of her feet and hands, and involuntary movements and a 
tremor in her lower limbs.   
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In her family history, her father died of dementia without motor problems aged 69y.  
She was admitted to hospital for investigation aged 60y.  On examination there was akinetic 
mutism with marked axial rigidity.  There was left laterocollis, minor right torticollis, perioral 
movements and occasional right cheek movements. There was broken pursuit and slow 
broken saccades.  There was moderate rigidity with spasticity in the upper limbs and severe 
rigidity in the lower limbs.  Plantars were extensor.  Palmomental and pout reflexes were 
present.  There was perseveration and frontal features.  MMSE (mini mental state 
examination) was 16/25.  (See supplementary information, case 1, for more detail of clinical 
investigations undertaken.) 
An unusual case: 
Case 7, a right-handed Caucasian man, had a normal birth and early development.  Aged 
three at nursery school, it was noted that he did not mix well with the other children.  At 
primary school aged five he was found to have slight difficulties with writing; aged six he 
was unable to follow basic lessons.  Soon thereafter he was seen by an educational 
psychologist and was diagnosed as having moderate learning difficulties and was 
transferred to special needs school.  
By age 8y, he had abnormal movements under stress, particularly affecting his hands and 
head.  These became a lot more prominent from 21y when they affected his walking. 
Occasionally his right leg was noted to jerk uncontrollably from under him, and he had 
some falls.  The ‘fidgeting’ and jerking movements of hands and neck deteriorated.  From 
21y he had increased frustration and aggression. 
His parents are non-consanguineous.  His maternal grandmother died of motor neuron 
disease; both parents were well.   
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Aged 23y he was admitted to hospital for investigation.  Gait was slightly broad based, with 
both arms tending to hold slightly dystonic postures, particularly on the right.  There was 
decreased arm swing, nuchal more than axial rigidity, unsteadiness on heel-toe walking, 
and Romberg’s test was negative.   Eye movements were abnormal, with poor gaze 
initiation, impaired pursuit, saccadic hypometria with head thrusts, and reduced vertical up-
gaze.  There was generalised chorea with mainly head and arm involvement, oro-buccal 
chorea, myoclonic movements of the head and neck, and some additional dystonic 
elements with mild bradykinesia.  In the limbs there were prominent irregular myoclonic 
jerks, exacerbated by movement and stimuli.  Reflexes and sensation were normal.   
MMSE was 20/28.  On Neuropsychological examination, the Wechsler Adult Intelligence 
Scale-Revised was within the defective range consistent with learning difficulties.  There 
was evidence of memory impairment for visual and verbal memory.   
MRI scan showed one small lacune.  Nerve conduction studies and electromyography were 
normal. Electroencephalography revealed a diffuse and non-specific excess of theta activity 
with only a trace of alpha like activity.  Although the bursts of high voltage slow activity had 
a bursting paroxysmal quality no definite epileptiform activity was seen.  (See 
supplementary information, case 2, for more detail of clinical investigations undertaken.) 
 
Discussion  
Huntington’s disease is the most common genetically determined neurodegenerative 
disease with a prevalence of at least 12.4 per 100,000 people24,  but in those in whom HD 
is suspected but patients do not have a CAG repeat expansion in HTT, attaining genetic 
diagnosis has been rare (2.8%20).  Here we present data demonstrating that the C9orf72 
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expansion is the commonest-identified genetic cause of HD phenocopy presentations in a 
UK cohort, with a prevalence of 1.95% (95% CI 1-4).   
 
HD is an autosomal dominant condition, classically presenting with a triad of movement, 
cognitive and psychiatric symptoms.  However there is clinical heterogeneity, particularly 
early in disease, and not all characteristic features may be apparent:  90% of adults with 
HD develop chorea, but the clinical spectrum is broad, including Parkinsonian akinetic-rigid 
syndromes and relatively pure dystonic, ataxic and psychiatric presentations25.   Around 8% 
of patients with HD present without an apparent family history of HD26.  Because of this 
clinical diversity, it is accepted3, 20 that any definition of Huntington’s disease phenocopy 
syndromes need encompass not only the classical triad of HD but also syndromes having a 
major degree of overlap with HD, and those without a known autosomal dominant family 
history.  Those patients with a clear family history of HD and with classical manifest HD are 
more likely to have HD, however many patients seen by Neurologists do not present in 
such a clear cut manner.  Our cohort is composed of patients seen by experienced 
neurologists in whom the diagnosis of HD was considered thus it reflects clinical reality.  It 
is UK-based, and given that UK-based cohorts have similar ethnic descent to other 
European, Australian and North American cohorts, our findings are likely to be 
representative of cohorts from these areas.  In patients of African origin (particularly 
Southern Africans), JPH3 expansion remains the commonest cause of HD-like 
presentations27.  Identifying the causes of HD phenocopy syndromes is of importance to the 
diagnosis and management of patients with these presentations, as well as the counselling 
of such individuals and their relatives in matters of genetic testing, life choices and 
reproduction3.   
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Diagnostic tests for this novel mutation have recently become available.  Many symptoms 
characteristic of HD were associated with the subject being C9orf72 positive; given this, 
and the high frequency of C9orf72 expansion among HD phenocopies mean that we 
believe that it should be tested for in all HD phenocopy cases.  In the future it is likely that 
multi-gene ‘disease panels’ will supersede the need for sequential genetic testing, however 
since C9orf72, like many other causes of HD phenocopies is an expansion mutation, it will 
remain important for the clinician to be aware of which tests are most appropriate for 
different patients and request them accordingly.  We propose a revised clinico-genetic 
algorithm for the investigation of HD phenocopy cases in Figure 2. 
 
Figure 2: ‘Algorithm for the investigation of HD phenocopy cases’.  
 
The effects of the C9orf72 expansion are known to be both clinically and pathologically 
varied28 and it is the major cause of both familial and sporadic ALS and FTLD, which are 
themselves phenotypically heterogeneous conditions.    Parkinsonism, particularly rigidity 
and bradykinesia, has been previously noted in C9orf72-positive individuals29-31; the 
C9orf72 mutation has been found in some cohorts of patients with Parkinson’s disease32 
and not others30, 33, 34.  In this study we have demonstrated that the clinical phenotypes 
caused by C9orf72 expansion mutations are broader than previously noted to date.  It can 
present with a movement disorder including chorea, dystonia, myoclonus and tremor. The 
combination of movement disorder, cognitive decline and psychiatric and behavioural 
problems, often with a family history of similar problems, explains why C9orf72-positive 
cases can have a presentation very similar to HD.  It is notable that ALS-type symptoms 
were relatively infrequent in the HD phenocopy C9orf72 cases: none had lower motor 
neuron signs, while 40% had upper motor neuron signs.  By contrast, symptoms more 
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characteristic of FTLD such as cognitive impairment were much more prevalent, suggesting 
that there is more overlap between the HD-like and FTLD-like cases.  
 
The average age of onset for C9orf72 in published reports is around 57 years7, 9, 31, 35, in 
this study it is lower at 42.7 years, with range 8 – 60, suggesting that the condition should 
be considered in the differential diagnosis not only in a wider range of clinical presentations, 
but in a wider demographic group than previously identified.    
 
We examined whether the difference in phenotype could be accounted for by a different 
size of expansion by Southern hybridisation: the size of expansion in our HD phenocopy 
cohort was not significantly different from that of other cohorts14.  Furthermore, among the 8 
C9orf72-positive subjects examined here, there is no statistically significant association 
between expansion size and age of onset.  Case 7, who had motor onset at 8y, underwent 
whole-exome sequencing; no large-scale structural abnormalities were detected.  An 
important caveat is that there is evidence of reduced penetrance of the C9orf72 expansion 
given that the population frequency of C9orf72 expansion is 1 in 69114 in the UK population, 
so there is a small possibility of false positives accounting for one or more of these unusual 
presentations of C9orf72 mutations. 
 
Among the ten HD phenocopy C9orf72 cases, there was a tendency for those with chorea 
and dystonia to have younger ages of onset than those without them: the average age of 
onset of subjects with chorea/ dystonia in this cohort is 28.3, whereas the average age of 
onset of those without them is 54.8 (P=0.019, Independent samples Mann-Whitney U-test).  
This may reflect our ascertainment criteria, since HD-phenocopy cases are more likely to 
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be young and have movement disorders than FTLD or ALS cases. However, it is possible 
that the C9orf72 expansion with these motor symptoms manifests with earlier onset.   
 
Incomplete penetrance has been previously suggested in C9orf72 expanded individuals36, 
13, 31 which has important implications for genetic testing.  In this case series there was no 
reported family history in three cases, and case 7’s family history is compatible with 
incomplete penetrance – the subject’s maternal grandmother had MND, but the mother was 
well. 
   
We have presented a large case series which not only demonstrates that the C9orf72 
expansion is the most frequent cause of HD phenocopy presentations in this UK-based 
population, but also that the phenotype of the C9orf72 encompasses a diversity of 
movement disorders, and a younger age of onset than previously recorded.  
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Figure Legends 
Figure 1: ‘Southern Blot of eight HD phenocopy patient DNAs’. Southern Blot of eight HD phenocopy patient 
DNAs, showing that C9orf72 repeat expansions can be seen in all cases. The asterisk indicates a GGGGCC 
containing a short-tandem-repeat genome motif unrelated to C9orf72.  The samples are ordered from 1 – 8 
from left to right; there was insufficient DNA to blot samples 9 and 10.  The blot for cases 1 – 6 has been 
previously published14.  (Reprinted with permission from Elsevier.) 
Figure 2: ‘Algorithm for the investigation of HD phenocopy cases’. Proposed clinico-genetic algorithm for the 
work-up of Huntington’s disease phenocopy patients, highlighting key diagnoses to be considered.  SCA, 
Spinocerebellar ataxia; HDL2, Huntington’s disease-like 2, DRPLA, dentatorubral-pallidoluysian atrophy; 
NBIA, Neurodegeneration with Brain Iron Accumulation.  
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Subject Age 
at 
onset 
Rs3849942 
genotype 
Expansion size 
estimated by 
southern 
hybridisation 
Goldman 
score 
1 60 AA 4010 4.5 
2 56 GA 3441 1 
3 55 AA 3682 1 
4 36 AA 3180 1 
5 50 GA 2939 3 
6 56 GA 2939 0 
7 8 GA 3186 3 
8 44 GA  3518 3 
9 19 AA insufficient DNA 4.5 
10 58 GA insufficient DNA 3 
Table 1: Age at onset and genetic results of C9orf72 
expansion positive cases 
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Clinical 
feature 
1 2 3 4 5 6 7 8 9 10 
Chorea     √  √  √  
Myoclonus √   √ √  √    
Dystonia    √ √  √  √  
Tremor     √   √  √ 
Rigidity   √ √ √  √ √  √ 
Bradykinesia    √ √  √ √  √ 
Torticollis    √ √   √   
UMN signs    √ √   √  √ 
Depression   √ √ √   √   
Anxiety √ √         
Apathy    √ √      
Executive 
dysfunction 
√ √ √ √    √  √ 
Impaired 
memory 
 √ √ √ √  √   √ 
Impaired 
face 
recognition 
 √ √    √    
Impaired 
verbal 
√    √     √ 
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fluency 
Table 2: Summary of the clinical features of ten C9orf72 expansion-positive cases. 
UMN = upper motor neuron.  
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 Number in 
C9orf72 negative 
cases (N=504) 
(Percentage) 
Number in C9orf72 
positive cases 
(N=10) 
(Percentage) 
Number in 
whole HD 
phenocopy 
cohort (N=514) 
(Percentage) 
P value 
(Fisher's exact 
test) 
All 
movement 
disorder 
features 
394 (78%) 8 (80%) 402 (78%) 1 
Chorea 154 (31%) 3 (30%) 157 (31%) 1 
Dystonia 53 (11%) 4 (40%) 57 (11.1%) 0.017 
Bradykinesi
a/ rigidity 
78 (15%) 6 (60%) 84 (16%) 0.002 
Tremor 39 (8%) 3 (30%) 42 (8%) 0.041 
Ataxia 72 (14%) 1 (10%) 73 (14%) 1 
Myoclonus 31 (6%) 4 (40%) 35 (7%) 0.003 
UMN 
features 
18 (4%) 4 (40%) 24 (5%) <0.001 
LMN 
features 
8 (1.6%) 0 (0%) 8 (2%) 1 
Psychiatric 
problems 
53 (11%) 7 (70%) 60 (12%) <0.001 
Depression 17 (3%) 4 (40%) 21 (4%) 0.035 
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Anxiety 4 (0.8%) 2 (20%) 6 (1%) 0.005 
Cognitive 
impairment 
167 (33%) 9 (90%) 176 (34%) <0.001 
Executive 
dysfunction 
19 (4%) 6 (60%) 25 (5%) <0.001 
Memory 
problems 
29 (6%) 9 (90%) 176 (34%) <0.001 
Family 
history 
98 (19%) 7 (70%) 105 (20%) 0.001 
Table 3: Phenotypic features of C9orf72 negative & positive cases within HD 
phenocopy cohort, and outcome of Fisher's exact test to test for association 
between clinical feature and genetic test outcome.  
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